Table 2. Medication adherence, persistence, and time until discontinuation of PsA patients treated with anti-TNF drugs.
| Anti-TNF | Adherence; n (%) | Persistence; n (%) | Time until discontinuation; mean (SD) |
|---|---|---|---|
| Adalimumab (n =112) | 85 (75.9) | 82 (73.2) | 325.34 (SD=85.55) |
| Etanercept (n=64) | 43 (67.2) | 40 (62.5) | 302.81 (SD=104.77) |
| Infliximab (n=21) | 19 (90.5) | 20 (95.2) | 356.52 (SD=38.84) |
| Total | 147 (74.6) | 142 (72.1) | 321.35 (SD=89.89) |
| P-value1 | 0.212 | 0.138 | 0.323 |
| P-value2 | 0.137 | 0.028 | 0.426 |
| P-value3 | 0.037 | 0.004 | 0.052 |
n: Number of patients; SD: Standard deviation
p-value1: adalimumab vs etanercept; p-value2: adalimumab vs infliximab; p-value3: etanercept vs infliximab